Laboratoire Aguettant’s Post

Phase III Study of Lisaftoclax in Newly-Diagnosed MDS Cleared Ascentage Pharma (6855.HK) announced today it has been cleared by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) to initiate a registrational Phase III study of lisaftoclax (APG-2575), one of the company’s key drug candidates, in combination with azacitidine (AZA) for the first-line treatment of newly-diagnosed patients with higher-risk myelodysplastic syndrome (MDS). This clears the fourth registrational Phase III study of lisaftoclax, marking another major milestone in the clinical development of the drug. Read More: https://lnkd.in/ecbXi6QN

The global ophthalmic drug market is predicted to surge by 6.39% to 2033 - incredible news! Check out the new #Pharma report here > https://ow.ly/BSqW50PoPlX to stay ahead in this fast-growing industry!

The global ophthalmic drug market is predicted to surge by 6.39% to 2033 - incredible news! Check out the new #Pharma report here > https://ow.ly/BSqW50PoPlX to stay ahead in this fast-growing industry!

📰 Thank you to MedNous (Evernow Publishing Ltd) for the great interview featuring our CEO and co-founder, Catherine Pickering, in its recent July-August 2024 edition! Great to see #iOnctura highlighted in Mednous' 'Small company, big theme' section focusing on how we are pursuing drug resistance.   💡 Make sure to check out the article on page 5 for an insightful read!   #cancer #oncology #biotech #lifesciences

NEWS! 👉Johnson & Johnson (J&J) is buying the rights to a new eczema treatment from Numab Therapeutics AG for about $1.25 billion. 👉This is J&J's second purchase of an eczema-focused company this month. 👉They bought Proteologix earlier for $850 million. Numab's drug, NM26, has just passed early testing and targets two disease pathways at once. 👉Eczema, also known as atopic dermatitis, affects 30 million people each year in the U.S. J&J is focusing on medical devices and drugs, making big deals like buying Shockwave Medical for $13.1 billion. 👉They are preparing for competition for their psoriasis drug Stelara in 2025. The deal with Numab should be finalized in the second half of 2024. #acquisition #numabtherapeutics #Proteologix #eczema #NM26 #atopicdermatitis #Johnsonandjohnson #healthcare

The global ophthalmic drug market is predicted to surge by 6.39% to 2033 - incredible news! Check out the new #Pharma report here > https://ow.ly/BSqW50PoPlX to stay ahead in this fast-growing industry!

A new weekly injectable weight-loss drug, pemvidutide, from Altimmune, showed impressive results in a Phase II clinical trial, with patients losing about 75% fat and only 25% muscle. This stands out compared to existing GLP-1 drugs, offering the potential to mimic exercise effects without physical activity. Other drugmakers are likewise exploring solutions to prevent muscle loss.</div><div class="read-more"><a href="" class="more-link">Continue reading</a>https://lnkd.in/eVUrjtsB

This story is now free to read: For the second time in recent months, the FDA's Oncologic Drugs Advisory Committee is using the presence of a pending application to debate potential changes to the broader field of drugs in the same class and indication. https://lnkd.in/eYAwMZW4

Delighted to announce the publication of a pre-print by the esteemed HESI Cardiac Safety Committee (https://lnkd.in/gMDu5VY) describing a new Cardiac Compound Tool Database! This new database (https://lnkd.in/gKYRrX3z) contains information on 128 pharmaceutical agents, including their cardiotoxic properties. Curated by subject matter experts and sourced from reputable literature and online databases, this resource provides details such as compound name, mode of action, cardiac toxicity profile, and more. The user-friendly interface allows for easy access and submission of new data, ensuring the database remains up-to-date and valuable for safety assessment and research on drug-induced cardiac toxicity. Read the full pre-print here: https://lnkd.in/gjR8dpAu

Thoughts on this? >> Roche was in 'advanced' talks to out-license its Angelman syndrome drug, but potential partner withdrew >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #productmarketing #biotech